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Objectives: There is limited timely information about healthcare spending in 
the US for those people under 65 with employer-sponsored insurance. This study 
explores the methods needed to use a large administrative database to fill this 
need. The fully implemented methodology will be used to portray recent trends 
in overall spending and highlight the role of prescription drugs in the context of 
those trends. MethOds: The Truven Health MarketScan database is updated each 
calendar quarter. This convenience sample is weighted to reflect the age, sex, and 
location characteristics of the US population with employer-sponsored insurance 
as captured by the US Medical Expenditure Panel Survey. Recent quarterly spending 
is adjusted for incurred but not yet reported services using a combination of cor-
rection factors and time series analysis. Spending is classified either by setting or 
by provider type. Overall and subpopulation breakdowns are presented. Results: 
Per capita annual spending has seen a compound annual growth rate of 5.2% over 
the period of 2003–2013. While the 0–17 age group has seen the highest annual 
growth rate at 6.5% (from $1,476 in 2003 to $2,772 in 2013), the 45–64 age group 
continues to have a higher level of expenditure ($8,175) despite a lower annual 
growth rate of 4.1%. Outpatient spending grew faster (6.0%) than either inpatient 
(4.5%) or prescription drug (4.0%). In the most recent year there has been an uptick 
in prescription drug spending fueled almost entirely by new treatments for Hepatitis 
C. cOnclusiOns: It is possible to create a useful, timely index of spending for 
the under 65 population of the US with employer-sponsored insurance. Recent 
trends indicate a growth in spending for children and a recently revived growth 
for prescription drugs.
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Objectives: Literature is lacking on the temporal pattern of use of permanent steri-
lization procedures and the characteristics of women who undergo them. This study 
evaluated the temporal pattern of use of hysteroscopic sterilization (HS) vs. inter-
val laparoscopic bilateral tubal ligation (LBTL) and differences in characteristics of 
women who undergo permanent sterilization procedures. MethOds: Women aged 
15-49 years who had a claim for HS or LBTL procedures during 1/1/2003-12/31/2012 
were identified from the Truven Health MarketScan Commercial Claims and 
Encounters database. The proportions and characteristics of women who underwent 
HS and LBTL were determined for the study population and subgroups stratified 
by year of procedure. Logistic regressions were used to identify predictors of use of 
HS vs. LBTL. Results: Among the study population, 32,012 had HS and 64,725 had 
LBTL. Women who had HS vs. LBTL were slightly older (37.2 vs. 36.4 years, p< 0.0001), 
but had similar Charlson Comorbidity Index scores. The proportion of women who 
had HS increased from 7% in 2005 to 45% in 2012. Compared to women who had 
a sterilization procedure between 2003 and 2007, women who had one between 
2008 and 2012 were more likely to undergo HS (Odds Ratio (OR): 7.1, p< 0.0001). 
Obesity was associated with a greater likelihood of having HS vs. LBTL (OR: 1.08, 
p= 0.03). Additionally, slightly greater age (OR: 1.03, p< 0.0001), having had a prior 
pregnancy/delivery (OR: 1.38, p< 0.0001), and having had prior oral contraceptive use 
(OR: 1.53, p< 0.0001) were associated with greater likelihoods of having had HS than 
LBTL. cOnclusiOns: Using a large claims database analysis, we observed among 
commercially-insured women that the likelihood of having HS vs. LBTL increased 
approximately 7-fold in years 2008-2012 from in years 2003-2007. Older age, prior 
pregnancy/delivery, and prior oral contraceptive use were associated with a greater 
likelihood of having HS vs. LBTL.
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Objectives: Migraine is a debilitating chronic disease that affects approximately 
13% of the United States population. Gender differences in migraine treatment have 
been studied; however, the results are often overlooked due to lack of controlling 
for selection bias. The study aimed to investigate gender differences in migraine 
treatment, using propensity score-matched analyses. MethOds: A retrospective 
population-based study was conducted by analyzing a national database from 2010 
National Ambulatory Medical Care Survey. All patient visits with a diagnosis of 
migraine were included. A series of weighted descriptive analyses were used to 
estimate the prevalence of medications recommended in the American Neurology 
Association practice guidelines. Multivariate logistic regression and Greedy 8 to 1 
digit match were used to create propensity scores. A propensity score weighted 
logistic regression model was fitted to compare the gender difference on migraine 
treatment while controlling for age, race, pay type, and physician specialty. All analy-
ses utilized SAS PROCSURVEY applications and incorporated sample weights and 
standard errors. Results: Among 5.45 million outpatient visits that took place in 
2010 with migraine diagnosis, female accounted for nearly four-times than male 
(79.8% vs. 20.2%). Of these, 3.08 million visits (56.48%) received at least one abortive 
or prophylactic migraine prescription. Prior to propensity-score matching, the socio-
economic characteristics of the two cohorts (with vs. without migraine pharmaco-
therapy) were significantly different (P< 0.001). After matching, there was no longer 
a significant difference between two cohorts (P> 0.05). Female received significant 
more migraine treatment than male (OR: 3.2, 95% CI: 1.137-8.932). cOnclusiOns: 
The assessment of gender differences in health care is challenging because of the 
potential biases that require careful adjustment. This study successfully reduced 
selection bias by propensity score-matched methodology and concluded significant 
gender disparity in migraine pharmacotherapy. This study also provides an empiri-
cal evident of undertreated migraine conditions in the US.
PIH65
TreaTMenT PaTTerns oF WoMen dIagnosed WITH uTerIne FIbroIds 5 
years Pre and PosT dIagnosIs: a longITudInal reTrosPecTIve claIMs 
analysIs oF a coMMercIally Insured PoPulaTIon In THe us
Soliman AM1, Fuldeore M1, Yang H2, Du EX2, Wu EQ2, Winkel C3
1AbbVie Inc., North Chicago, IL, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Georgetown 
University School of Medicine, Washington, DC, USA
Objectives: To evaluate treatment patterns among women with uterine fibroid (UF) 
versus matched controls for 5 years before and after diagnosis. MethOds: Women 
with a UF diagnosis (International Classification of Diseases 218.xx) aged 18-45 years 
were identified in Truven Health MarketScan® 2000-2010 data, and matched 1:1 to 
women without UF (control) by age, region, and insurance type. The first recorded 
UF diagnosis date was assigned as the index date for the UF patient and matched 
control. Continuous eligibility in a health plan for ≥ 1 year pre- and post-index was 
required. UF-related medications and surgical treatments during the five pre- and 
post-index years were evaluated annually, and compared between UF patients and 
controls using McNemar’s tests. Results: A total of 84,954 matched pairs, with a 
mean age of 39.3 years at the index date were included in the analysis. During the 
3 years prior to the index date, annual medication use (ranging from 18.7-19.5% 
vs. 16.5-18.4% for combined oral contraceptives and 0.4-0.9% vs. 0.2-0.3% for GnRH 
agonists) and UF-related surgery use (0.8-0.9% vs. 0.1-0.4% for endometrial abla-
tions), respectively, was significantly higher among UF patients than controls (all p 
values < 0.05). In the first year post-index, a greater proportion of UF patients than 
controls were treated with medications (combined oral contraceptives, 17.1% vs. 
15.6%; progestins, 10.7% vs. 4.9%; and GnRH agonists, 2.8% vs. 0.2%) and surgeries 
(hysterectomies, 27.9% vs. 0.5%; endometrial ablations, 6.3% vs. 0.6%; myomecto-
mies, 5.9% vs. < < 0.1%), respectively (all p values < 0.05). In the next four years of 
follow-up, the annual utilization difference decreased, but remained higher in UF 
patients and the differences were significant for GnRH agonist, hysterectomy, and 
myomectomy use. cOnclusiOns: Patients with UF used significantly more UF 
treatments than controls after diagnosis, and also during the period before diag-
nosis. Treatment usage peaked in the first year post-diagnosis.
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Objectives: Serotonin syndrome (SS) is an adverse drug reaction that may occur 
in patients receiving monotherapy or combinations of serotonergic agents (SAs). 
This study examined healthcare utilization and costs of SS in two different popu-
lations. MethOds: Adult (age ≥ 18 years) patients prescribed SAs were identified 
using the Veterans Health Administration (VHA) dataset (01OCT2008-30SEPT2012) and 
the IMS PharMetrics Plus dataset (01JAN2010-31DEC2013). Patients with continuous 
health plan enrollment 12 months pre-index date, defined as the first SA prescrip-
tion claim date, were included and observed until death, disenrollment or the end of 
the study period. Patients were assigned to cohorts based on drug exposure: single 
monoamine oxidase inhibitor (MAOI) drug, MAOI drugs in combination with other 
SAs, single non-MAOI SA, and multiple non-MAOI SAs (2, 3, 4, and ≥ 5 SAs). Outcomes 
of interest were annual incidences of SS event (ICD-9-CM: 333.99) and associated 
health care utilization and costs. Results: The incidence rate of SS was similar 
between veterans (VHA) and commercially insured patients (IMS) prescribed SAs and 
decreased over time (IMS: 0.17% in 2010 to 0.09% in 2013; VHA: 0.19% in 2009 to 0.07% 
in 2012). 0.88% and 4.35% of all SS events led to hospitalization in the IMS and VHA 
populations, respectively. Proportion of IMS patients with SS-related hospitalization 
increased as the number of non-MAOI SAs increased (0.24% for one drug vs. 6.93% for 
≥ 5 drugs). Average healthcare cost per SS event was higher in the MAOI combination 
cohort (IMS: $2,474; VHA: $2,896) and the ≥ 5 non-MAOI SAs cohort (IMS: $1,167; VHA: 
$3,837) than the single non-MAOI SA cohort. cOnclusiOns: The overall incidence 
of SS and proportion of serious SS leading to hospitalization are similar in the VHA 
and IMS populations. Use of MAOIs or multiple SAs concomitantly increases the risk 
of SS and leads to higher health care utilization and costs.
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Objectives: There is limited evidence regarding the role of anticholinergic medica-
tions in falls/fractures among the elderly. This study examined the risk of fractures 
associated with anticholinergic use in elderly nursing home residents with depres-
sion. MethOds: A population-based nested case control study was conducted 
using 2007-2010 Minimum Data Set (MDS)-linked Medicare data from all states. 
Patients with continuous coverage in Medicare Parts A, B, D and no HMO coverage 
during the study period or until death were considered. The base cohort included 
